Simulating disease progression through the four-part MDS-UPDRS scale — non-motor experiences, motor ADL, motor examination, and motor complications — mapped onto composite score and Hoehn-Yahr stage
Parkinson's disease is far more than a movement disorder. Part I of the MDS-UPDRS captures the non-motor experiences of daily living — cognitive change, neuropsychiatric symptoms, sleep disturbance, and autonomic dysfunction — that patients frequently rank as more disabling than tremor or slowness, yet that dopaminergic medication only partially addresses.
Part I is split into two administration formats:
Clinician-interview items (1a–1f): cognitive impairment, hallucinations and psychosis, depressed mood, anxious mood, apathy, and features of dopamine dysregulation syndrome (DDS) — compulsive medication use, punding, and impulse-control behaviors such as pathological gambling or hypersexuality.
Patient/caregiver questionnaire items (1.1–1.9, self-completed the week before the visit): sleep problems, daytime sleepiness, pain and other sensations, urinary problems, constipation, lightheadedness on standing (orthostatic symptoms), and fatigue.
Each item is scored 0 (normal) to 4 (severe), yielding a domain range of 0–52. Because items are answered from two perspectives — clinical judgment plus patient self-report — Part I is designed to catch symptoms that a brief motor-focused visit would otherwise miss entirely.
Longitudinal cohort studies consistently show that non-motor burden — not motor severity — is the strongest predictor of health-related quality of life, caregiver strain, and nursing-home placement in Parkinson's disease. Depression and apathy alone can be more disabling than moderate bradykinesia, and REM sleep behavior disorder (RBD) disrupts both patient and bed-partner sleep years before diagnosis.
Critically, most Part I domains respond poorly or unpredictably to levodopa: hallucinations and orthostatic hypotension can even worsen with dopaminergic escalation, forcing clinicians to balance motor control against non-motor tolerability. This is why Part I is scored and tracked independently — a patient can have an excellent Part III motor exam and still be severely impaired by unrecognized non-motor disease.
Hyposmia (loss of smell), constipation, and REM sleep behavior disorder are now recognized as prodromal markers that can appear a decade or more before the first tremor — driving research into pre-motor biomarker panels for early intervention trials.
Where Part III measures what a clinician observes in an exam room, Part II asks the patient directly: how hard is it to actually get through the day? Thirteen self-reported items translate abstract motor signs into the lived experience of speaking, eating, dressing, writing, and walking.
Part II items cover: speech, salivation and drooling, chewing and swallowing, eating tasks (cutting food, using utensils), dressing, hygiene, handwriting, doing hobbies and other activities, turning in bed, tremor's impact on activities, getting out of bed/car/deep chair, walking and balance, and freezing.
Each is rated by the patient (or caregiver, if needed) on how the past week actually went — not on a bad or good day in isolation. This self-report format captures fluctuation-related variability that a single clinic-visit exam cannot: a patient may walk normally during a 15-minute ON-state assessment yet freeze repeatedly at home during OFF periods.
Freezing of gait (FOG) — a sudden, brief inability to initiate or continue walking, often at doorways, turns, or destination approach — is one of the most disabling and treatment-resistant items in Part II. It is rare early in disease but affects roughly a third to half of patients by mid-to-late stage, and it is a leading cause of falls, fear of falling, and loss of independent mobility.
Unlike tremor or rigidity, FOG responds inconsistently to levodopa — some patients experience OFF-freezing that resolves with medication, while others develop ON-freezing that dopaminergic therapy cannot touch. This item alone often drives referral for physical therapy, cueing strategies, and in select cases deep brain stimulation targeting.
Part III is the clinical core of the entire scale: an 18-item, 33-score hands-on examination of bradykinesia, rigidity, tremor, gait, and postural stability, performed by a trained rater. It carries the largest score range and the greatest weight in most composite calculations, and it is the part most sensitive to medication state.
Bradykinesia: slowness and decrement of repetitive movement, assessed through finger tapping, hand opening/closing, pronation-supination, toe tapping, and leg agility. The hallmark is not just slowness but progressive decrement in amplitude across repetitions — movements that start reasonably sized and shrink with each cycle.
Rigidity: resistance to passive movement about a joint, assessed at neck, arms, and legs. Classically described as 'lead-pipe' (constant resistance) or 'cogwheel' (ratchet-like, when tremor is superimposed).
Tremor: rated separately for rest tremor (amplitude and constancy, per limb, 4–6 Hz), postural tremor, and kinetic tremor (during a targeted reaching movement).
Postural instability and gait: arising from a chair, gait quality, freezing during the exam, and the retropulsion 'pull test' — a sudden backward shoulder pull to assess corrective stepping. A positive pull test (more than one retropulsive step, or no corrective response) is a key marker of advancing disease and correlates with Hoehn-Yahr stage III.
Because Part III responds dramatically to dopaminergic medication, guidelines require raters to record the patient's clinical state — OFF (typically after an overnight medication withdrawal) versus ON (after a standard levodopa dose, at peak benefit). The difference between OFF and ON Part III scores, expressed as percentage improvement, is the single most common outcome measure in clinical trials and is also used to screen candidates for deep brain stimulation: a robust levodopa response is generally a prerequisite for a favorable DBS outcome.
A patient's OFF-to-ON Part III improvement of 30% or more is a commonly used clinical threshold supporting good candidacy for subthalamic nucleus deep brain stimulation, since DBS broadly mimics the pattern (though not the full magnitude) of the dopaminergic response.
Years of pulsatile levodopa dosing reshape how the striatum responds to dopamine, producing two treatment-related complications: involuntary dyskinetic movements and unpredictable ON/OFF motor fluctuations. Part IV's six items — the smallest but clinically pivotal part of the scale — quantify how much time these complications occupy and how disabling they are.
Dyskinesia items: time spent with dyskinesia (as a fraction of the waking day) and the functional impact of that dyskinesia on daily activities.
Motor fluctuation items: time spent in the OFF state, the functional impact of those fluctuations, and the complexity of the fluctuations (how unpredictable the transitions between ON and OFF are — sudden 'ON-OFF' switching is rated as more complex, and more disabling, than gradual predictable wearing-off).
Painful OFF-state dystonia: a distinct item capturing involuntary, often painful sustained muscle contractions — commonly early-morning foot dystonia — that occur specifically when dopaminergic levels trough.
Levodopa-induced dyskinesia (LID) is thought to arise from non-physiological, pulsatile stimulation of striatal dopamine receptors: healthy dopaminergic neurons release dopamine in a smooth, tonic pattern, but oral levodopa produces peaks and troughs that drive maladaptive synaptic plasticity in the direct and indirect basal ganglia pathways. Over years, this remodels striatal output until movements — often peak-dose choreiform (dance-like) — occur even when the underlying parkinsonism is well controlled.
Strategies to reduce Part IV burden generally aim to smooth dopaminergic stimulation: continuous levodopa-carbidopa intestinal gel infusion, subcutaneous apomorphine or foslevodopa infusion, MAO-B/COMT inhibitor adjuncts to extend each dose's effect, and deep brain stimulation, which allows lower total levodopa dosing while maintaining motor control.
Motor fluctuations and dyskinesia are markers of advancing disease, not medication failure — they reflect progressive loss of the striatal dopamine terminals that normally buffer and smooth an oral drug's pharmacokinetics into steady physiological signaling.
No single visit's score tells the full story of Parkinson's disease — it is the trend across years that reveals rate of progression, response to treatment changes, and approaching disability milestones. Alongside the granular four-part MDS-UPDRS, the simpler five-stage Hoehn-Yahr scale remains the most widely used shorthand for overall disease severity.
For longitudinal tracking, the four MDS-UPDRS parts are typically summed into a total score (0–260) or, for illustrative dashboards like this one, blended into a normalized 0–100 composite weighted toward the objective motor exam (Part III), which is the most reproducible and treatment-responsive component. Tracking the composite alongside its four sub-scores over successive visits reveals which domain is driving overall change — a rising Part IV with a flat Part III, for instance, points to emerging treatment complications rather than underlying disease worsening.
Because Part III itself can swing 30% or more between ON and OFF states, natural-history and trial protocols standardize the medication state at each visit so that year-over-year comparisons reflect true disease change rather than dosing-schedule noise.
Introduced in 1967 and modified in 2004, the Hoehn-Yahr scale grades overall disability from unilateral signs through bilateral involvement, the emergence of postural instability, and ultimately loss of independent mobility. It correlates loosely with composite UPDRS ranges but is valued clinically for its simplicity and its strong association with falls risk and independence.
Postural instability — the transition from Hoehn-Yahr stage II to III — is widely regarded as the single most important clinical milestone in Parkinson's disease, since it marks the point where fall risk rises sharply and it does not respond reliably to dopaminergic medication, unlike bradykinesia, rigidity, or tremor.
| Product | Indication | Trial Design | Key Result |
|---|---|---|---|